Loading...

Nexus

XTRA:NXU
Snowflake Description

Flawless balance sheet with moderate growth potential.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
NXU
XTRA
€500M
Market Cap
  1. Home
  2. DE
  3. Healthcare
Company description

Nexus AG develops and sells software and hardware solutions, and provides IT services for customers in the health care system worldwide. The last earnings update was 74 days ago. More info.


Add to Portfolio Compare Print
  • Nexus has significant price volatility in the past 3 months.
NXU Share Price and Events
7 Day Returns
8.5%
XTRA:NXU
1.2%
DE Healthcare Services
-1%
DE Market
1 Year Returns
23.3%
XTRA:NXU
45.5%
DE Healthcare Services
-6.2%
DE Market
NXU Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Nexus (NXU) 8.5% 1.3% 30.9% 23.3% 89.3% 165%
DE Healthcare Services 1.2% 5.6% 27.8% 45.5% 80.7% 224.5%
DE Market -1% 2.1% -1.8% -6.2% 10.4% 12.6%
1 Year Return vs Industry and Market
  • NXU underperformed the Healthcare Services industry which returned 45.5% over the past year.
  • NXU outperformed the Market in Germany which returned -6.2% over the past year.
Price Volatility
NXU
Industry
5yr Volatility vs Market

Value

 Is Nexus undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Nexus to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Nexus.

XTRA:NXU Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 4 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 6.6%
Perpetual Growth Rate 10-Year DE Government Bond Rate 0.2%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for XTRA:NXU
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year DE Govt Bond Rate 0.2%
Equity Risk Premium S&P Global 6%
Healthcare Services Unlevered Beta Simply Wall St/ S&P Global 1.08
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.082 (1 + (1- 30%) (1.72%))
1.064
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.06
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 0.23% + (1.064 * 5.96%)
6.57%

Discounted Cash Flow Calculation for XTRA:NXU using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Nexus is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

XTRA:NXU DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (EUR, Millions) Source Present Value
Discounted (@ 6.57%)
2020 19.90 Analyst x4 18.67
2021 21.85 Analyst x4 19.24
2022 20.60 Analyst x1 17.02
2023 21.80 Analyst x1 16.90
2024 22.14 Est @ 1.55% 16.11
2025 22.39 Est @ 1.15% 15.29
2026 22.59 Est @ 0.88% 14.47
2027 22.74 Est @ 0.68% 13.67
2028 22.87 Est @ 0.55% 12.90
2029 22.97 Est @ 0.45% 12.16
Present value of next 10 years cash flows €156.44
XTRA:NXU DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2029 × (1 + g) ÷ (Discount Rate – g)
= €22.97 × (1 + 0.23%) ÷ (6.57% – 0.23%)
€363.15
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= €363.15 ÷ (1 + 6.57%)10
€192.23
XTRA:NXU Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= €156.44 + €192.23
€348.67
Equity Value per Share
(EUR)
= Total value / Shares Outstanding
= €348.67 / 15.71
€22.19
XTRA:NXU Discount to Share Price
Calculation Result
Value per share (EUR) From above. €22.19
Current discount Discount to share price of €31.80
= -1 x (€31.80 - €22.19) / €22.19
-43.3%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

  • The current share price of Nexus is above its future cash flow value.
Often investors are willing to pay a premium for a company that has a high dividend or the potential for future growth.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Nexus's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Nexus's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
XTRA:NXU PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-03-31) in EUR €0.71
XTRA:NXU Share Price ** XTRA (2019-07-16) in EUR €31.8
Germany Healthcare Services Industry PE Ratio Median Figure of 6 Publicly-Listed Healthcare Services Companies 20.77x
Germany Market PE Ratio Median Figure of 419 Publicly-Listed Companies 19.92x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Nexus.

XTRA:NXU PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= XTRA:NXU Share Price ÷ EPS (both in EUR)

= 31.8 ÷ 0.71

44.95x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Nexus is overvalued based on earnings compared to the DE Healthcare Services industry average.
  • Nexus is overvalued based on earnings compared to the Germany market.
Price based on expected Growth
Does Nexus's expected growth come at a high price?
Raw Data
XTRA:NXU PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 44.95x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 4 Analysts
15.8%per year
Europe Healthcare Services Industry PEG Ratio Median Figure of 11 Publicly-Listed Healthcare Services Companies 1.85x
Germany Market PEG Ratio Median Figure of 270 Publicly-Listed Companies 1.48x

*Line of best fit is calculated by linear regression .

XTRA:NXU PEG (Price to Earnings to Growth) Ratio Calculation
Calculation Outcome
PEG Ratio

= PE Ratio ÷ Net Income Annual Growth Rate

= 44.95x ÷ 15.8%

2.85x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Nexus is poor value based on expected growth next year.
Price based on value of assets
What value do investors place on Nexus's assets?
Raw Data
XTRA:NXU PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-03-31) in EUR €7.00
XTRA:NXU Share Price * XTRA (2019-07-16) in EUR €31.8
Germany Healthcare Services Industry PB Ratio Median Figure of 7 Publicly-Listed Healthcare Services Companies 2.06x
Germany Market PB Ratio Median Figure of 565 Publicly-Listed Companies 1.75x
XTRA:NXU PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= XTRA:NXU Share Price ÷ Book Value per Share (both in EUR)

= 31.8 ÷ 7.00

4.54x

* Primary Listing of Nexus.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Nexus is overvalued based on assets compared to the DE Healthcare Services industry average.
X
Value checks
We assess Nexus's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Healthcare Services industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Healthcare Services industry average (and greater than 0)? (1 check)
  5. Nexus has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Nexus expected to perform in the next 1 to 3 years based on estimates from 4 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
15.8%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Nexus expected to grow at an attractive rate?
  • Nexus's earnings growth is expected to exceed the low risk savings rate of 0.2%.
Growth vs Market Checks
  • Nexus's earnings growth is expected to exceed the Germany market average.
  • Nexus's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
XTRA:NXU Future Growth Rates Data Sources
Data Point Source Value (per year)
XTRA:NXU Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 4 Analysts 15.8%
XTRA:NXU Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 4 Analysts 5.7%
Germany Healthcare Services Industry Earnings Growth Rate Market Cap Weighted Average 7.7%
Europe Healthcare Services Industry Revenue Growth Rate Market Cap Weighted Average 6.5%
Germany Market Earnings Growth Rate Market Cap Weighted Average 12.1%
Germany Market Revenue Growth Rate Market Cap Weighted Average 5.2%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
XTRA:NXU Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below
All numbers in EUR Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
XTRA:NXU Future Estimates Data
Date (Data in EUR Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 183 1
2022-12-31 176 1
2021-12-31 172 33 19 3
2020-12-31 159 30 18 4
2019-12-31 148 31 15 4
XTRA:NXU Past Financials Data
Date (Data in EUR Millions) Revenue Cash Flow Net Income *
2019-03-31 144 29 11
2018-12-31 141 20 11
2018-09-30 133 22 11
2018-06-30 130 22 10
2018-03-31 127 21 10
2017-12-31 124 22 10
2017-09-30 121 21 9
2017-06-30 119 20 9
2017-03-31 115 21 8
2016-12-31 112 17 8
2016-09-30 110 20 8
2016-06-30 108 22 7

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Nexus's earnings are expected to grow by 15.8% yearly, however this is not considered high growth (20% yearly).
  • Nexus's revenue is expected to grow by 5.7% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
XTRA:NXU Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below

All data from Nexus Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

XTRA:NXU Future Estimates Data
Date (Data in EUR Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31 1.22 1.39 1.01 3.00
2020-12-31 1.12 1.32 0.89 4.00
2019-12-31 0.96 1.18 0.80 4.00
XTRA:NXU Past Financials Data
Date (Data in EUR Millions) EPS *
2019-03-31 0.71
2018-12-31 0.69
2018-09-30 0.67
2018-06-30 0.64
2018-03-31 0.64
2017-12-31 0.63
2017-09-30 0.58
2017-06-30 0.54
2017-03-31 0.52
2016-12-31 0.52
2016-09-30 0.48
2016-06-30 0.48

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Nexus is not expected to efficiently use shareholders’ funds in the future (Return on Equity less than 20%).
X
Future performance checks
We assess Nexus's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Europe market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Nexus has a total score of 3/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Nexus performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Nexus's growth in the last year to its industry (Healthcare Services).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Nexus's year on year earnings growth rate has been positive over the past 5 years.
  • Nexus's 1-year earnings growth exceeds its 5-year average (9.9% vs 7.5%)
  • Nexus's earnings growth has not exceeded the DE Healthcare Services industry average in the past year (9.9% vs 106.7%).
Earnings and Revenue History
Nexus's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Nexus Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

XTRA:NXU Past Revenue, Cash Flow and Net Income Data
Date (Data in EUR Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-03-31 143.75 11.13
2018-12-31 140.60 10.92
2018-09-30 133.05 10.50
2018-06-30 129.98 10.11
2018-03-31 127.13 10.13
2017-12-31 124.14 9.83
2017-09-30 121.23 9.06
2017-06-30 118.92 8.56
2017-03-31 115.12 8.19
2016-12-31 112.50 8.15
2016-09-30 110.36 7.60
2016-06-30 107.56 7.50
2016-03-31 106.08 7.72
2015-12-31 102.56 7.58
2015-09-30 98.93 9.04
2015-06-30 94.36 8.91
2015-03-31 89.08 8.43
2014-12-31 84.83 8.28
2014-09-30 81.79 7.24
2014-06-30 81.49 7.50
2014-03-31 79.74 7.36
2013-12-31 77.78 7.22
2013-09-30 74.90 6.95
2013-06-30 72.03 6.64
2013-03-31 69.74 6.49
2012-12-31 66.64 6.09
2012-09-30 63.29 5.75

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • Nexus has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
  • Nexus used its assets less efficiently than the DE Healthcare Services industry average last year based on Return on Assets.
  • Nexus's use of capital deteriorated last year versus 3 years ago (Return on Capital Employed).
X
Past performance checks
We assess Nexus's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Healthcare Services industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Nexus has a total score of 2/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Nexus's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Nexus's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Nexus is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Nexus's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Nexus's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Nexus has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Nexus Company Filings, last reported 3 months ago.

XTRA:NXU Past Debt and Equity Data
Date (Data in EUR Millions) Total Equity Total Debt Cash & Short Term Investments
2019-03-31 110.71 0.00 51.03
2018-12-31 108.33 9.00 52.32
2018-09-30 108.50 0.00 24.91
2018-06-30 105.83 0.00 25.52
2018-03-31 104.48 0.00 37.44
2017-12-31 103.01 0.00 27.23
2017-09-30 100.74 0.00 27.98
2017-06-30 96.95 0.00 29.91
2017-03-31 98.34 0.00 34.51
2016-12-31 95.80 0.00 16.23
2016-09-30 93.50 0.00 20.84
2016-06-30 91.55 0.00 27.92
2016-03-31 91.44 0.01 33.26
2015-12-31 89.06 0.01 20.24
2015-09-30 89.64 0.02 20.18
2015-06-30 88.79 0.02 21.05
2015-03-31 88.44 4.75 29.26
2014-12-31 75.81 0.27 16.07
2014-09-30 76.01 0.06 26.74
2014-06-30 74.33 0.26 25.78
2014-03-31 74.27 0.08 30.93
2013-12-31 71.50 0.20 18.71
2013-09-30 71.01 0.06 25.07
2013-06-30 69.42 0.18 23.98
2013-03-31 69.50 0.12 27.66
2012-12-31 68.11 0.39 15.45
2012-09-30 60.59 0.08 25.43
  • Nexus has no debt.
  • Nexus has no debt compared to 5 years ago when it was 0.1%.
  • Nexus has no debt, it does not need to be covered by operating cash flow.
  • Nexus has no debt, therefore coverage of interest payments is not a concern.
X
Financial health checks
We assess Nexus's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Nexus has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Nexus's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0.53%
Current annual income from Nexus dividends. Estimated to be 0.6% next year.
If you bought €2,000 of Nexus shares you are expected to receive €11 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Nexus's pays a lower dividend yield than the bottom 25% of dividend payers in Germany (1.46%).
  • Nexus's dividend is below the markets top 25% of dividend payers in Germany (3.82%).
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
XTRA:NXU Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below
Europe Healthcare Services Industry Average Dividend Yield Market Cap Weighted Average of 10 Stocks 1.5%
Germany Market Average Dividend Yield Market Cap Weighted Average of 325 Stocks 3.1%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.5%
Germany Top 25% Dividend Yield 75th Percentile 3.8%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

XTRA:NXU Future Dividends Estimate Data
Date (Data in €) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31 0.20 4.00
2020-12-31 0.19 4.00
2019-12-31 0.18 4.00
XTRA:NXU Past Annualized Dividends Data
Date (Data in €) Dividend per share (annual) Avg. Yield (%)
2019-03-05 0.170 0.627
2018-03-06 0.160 0.614
2017-03-21 0.150 0.609
2016-03-22 0.140 0.786
2015-08-18 0.130 0.750
2015-03-25 0.130 0.777
2014-05-15 0.120 0.965
2014-03-25 0.110 0.956
2013-11-11 0.000 0.000
2013-05-10 0.110 1.137
2013-03-25 0.000 0.000

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Nexus is not paying a notable dividend for Germany, therefore no need to check if the payments are stable.
  • Nexus is not paying a notable dividend for Germany, therefore no need to check if the payments are increasing.
Current Payout to shareholders
What portion of Nexus's earnings are paid to the shareholders as a dividend.
  • No need to calculate the sustainability of Nexus's dividends as it is not paying a notable one for Germany.
Future Payout to shareholders
  • No need to calculate the sustainability of Nexus's dividends in 3 years as they are not expected to pay a notable one for Germany.
X
Income/ dividend checks
We assess Nexus's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Nexus afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Nexus has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Nexus's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Ingo Behrendt
COMPENSATION €713,000
CEO Bio

Dr. Ingo Behrendt, MBA serves as the Chairman of the Executive Board and Chief Executive Officer at Nexus AG.

CEO Compensation
  • Ingo's compensation has increased by more than 20% in the past year whilst earnings grew less than 20%.
  • Ingo's remuneration is about average for companies of similar size in Germany.
Management Team

Ingo Behrendt

TITLE
Chairman of the Executive Board & CEO
COMPENSATION
€713K

Ralf Heilig

TITLE
Chief Sales Officer
COMPENSATION
€325K
TENURE
10.5 yrs

Edgar Kuner

TITLE
Chief Development Officer & Member of Executive Board
COMPENSATION
€304K
TENURE
10.5 yrs
Board of Directors Tenure

Average tenure of the Nexus board of directors in years:

5.7
Average Tenure
  • The tenure for the Nexus board of directors is about average.
Board of Directors

Hans-Joachim Konig

TITLE
Chairman of the Supervisory Board

Ulrich Krystek

TITLE
Deputy Chairman of the Supervisory Board
TENURE
7.2 yrs

Alexander Pocsay

TITLE
Member of the Supervisory Board
TENURE
13.1 yrs

Wolfgang Dorflinger

TITLE
Member of the Supervisory Board

Gerald Glasauer

TITLE
Member of he Supervisory Board
AGE
50
TENURE
4.2 yrs

Felicia Rosenthal

TITLE
Member of the Supervisory Board
TENURE
4.2 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
X
Management checks
We assess Nexus's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Nexus has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

The Nexus (ETR:NXU) Share Price Is Up 151% And Shareholders Are Boasting About It

Over half a decade, Nexus managed to grow its earnings per share at 7.7% a year. … It is important to consider the total shareholder return, as well as the share price return, for any given stock. … A Different Perspective It's nice to see that Nexus shareholders have received a total shareholder return of 12% over the last year.

Simply Wall St -

Is Nexus AG's (ETR:NXU) CEO Paid At A Competitive Rate?

According to our data, Nexus AG has a market capitalization of €512m, and pays its CEO total annual compensation worth €713k. … We examined companies with market caps from €177m to €707m, and discovered that the median CEO total compensation of that group was €730k. … Boasting a total shareholder return of 95% over three years, Nexus AG has done well by shareholders.

Simply Wall St -

Don't Sell Nexus AG (ETR:NXU) Before You Read This

The formula for price to earnings is: Price to Earnings Ratio = Price per Share ÷ Earnings per Share (EPS) Or for Nexus: P/E of 42.97 = €30.4 ÷ €0.71 (Based on the trailing twelve months to March 2019.) Is A High Price-to-Earnings Ratio Good? … The higher the P/E ratio, the higher the price tag of a business, relative to its trailing earnings. … How Growth Rates Impact P/E Ratios P/E ratios primarily reflect market expectations around earnings growth rates.

Simply Wall St -

Is Nexus AG's (ETR:NXU) Growth Strong Enough To Justify Its May Share Price?

Nexus AG (ETR:NXU) closed yesterday at €25.9, which left some investors asking whether the high earnings potential can still be justified at this price. … This tells us that Nexus is overvalued compared to the DE market average ratio of 20.44x , and overvalued based on current earnings compared to the Healthcare Services industry average of 24.93x. … XTRA:NXU Price Estimation Relative to Market, May 17th 2019 We understand NXU seems to be overvalued based on its current earnings, compared to its industry peers.

Simply Wall St -

What Should You Know About Nexus AG's (ETR:NXU) Long Term Outlook?

Want to participate in a short research study? … Help shape the future of investing tools and you could win a $250 gift card! … In December 2018, Nexus AG (ETR:NXU) announced its most recent earnings update, whicha

Simply Wall St -

Is Nexus AG (ETR:NXU) Investing Your Capital Efficiently?

In particular, we'll consider its Return On Capital Employed (ROCE), as that can give us insight into how profitably the company is able to employ capital in its business. … Return On Capital Employed (ROCE): What is it? … ROCE measures the amount of pre-tax profits a company can generate from the capital employed in its business.

Simply Wall St -

If You Had Bought Nexus (ETR:NXU) Shares Five Years Ago You'd Have Made 106%

For example, the Nexus AG (ETR:NXU) share price has soared 106% in the last half decade. … Meanwhile the share price is 3.0% higher than it was a week ago. … This EPS growth is slower than the share price growth of 16% per year, over the same period.

Simply Wall St -

Is Nexus AG's (ETR:NXU) 10% ROE Strong Compared To Its Industry?

Our data shows Nexus has a return on equity of 10% for the last year. … One way to conceptualize this, is that for each €1 of shareholders' equity it has, the company made €0.10 in profit. … Return on Equity = Net Profit ÷ Shareholders' Equity

Simply Wall St -

Should You Be Pleased About The CEO Pay At Nexus AG's (ETR:NXU)

This analysis aims first to contrast CEO compensation with other companies that have similar market capitalization. … How Does Ingo Behrendt's Compensation Compare With Similar Sized Companies. … At the time of writing our data says that Nexus AG has a market cap of €383m, and is paying total annual CEO compensation of €713k.

Simply Wall St -

What Type Of Shareholder Owns Nexus AG's (ETR:NXU)?

Companies that used to be publicly owned tend to have lower insider ownership. … With a market capitalization of €387m, Nexus is a small cap stock, so it might not be well known by many institutional investors. … institutional investors have bought into the company.

Simply Wall St -

Company Info

Description

Nexus AG develops and sells software and hardware solutions, and provides IT services for customers in the health care system worldwide. It operates in two divisions, Healthcare Software and Healthcare Services. The company offers information systems, such as NEXUS/HIS and TESIS for somatic hospitals; NEXUS/PSYCHIATRY for psychiatric institutions; NEXUS/ESKULAP and NEXUS/EPD for somatic and psychiatric institutions; NEXUS/VITA and TESIS VITA for in-vitro clinics; NEXUS/HOME for senior citizen and nursing homes; Emed, a web-based hospital information system; NEXUS/REHA for rehabilitation facilities; NEXUS/PAT(CH), an administration system for hospitals; NEXUS/GYNECOLOGY for obstetric institutes and gynecology; NEXUS/PATHOLOGY and NEXUS/CYTOLOGY for pathology and cytology institutes; NEXUS/RADIOLOGY, an information and image system for radiology wards and offices; NEXUS/INFORMATION STORE, a management information system for hospitals; NEXUS/QM for quality management in the healthcare system; and NEXUS/CSSD, NEXUS/SPM, and EuroSDS for product sterilization processes in hospitals. Its information systems also comprise NEXUS/INTEGRATIONSERVER for interface management; NEXUS/SPECIAL DIAGNOSTICS and Clinic WinData for medical diagnostics and device integration; NEXUS/OUTPATIENT CARE and Asebis, a homecare solution; NEXUS/ARCHIVE and PEGASOS, an archiving and process management system; NEXUS/SWITSPOT software solutions; ASS.TEC for process and HR consulting in SAP environment; highsystemNET life cycle client management; CREATIVE OM, CRM solution; and NEXUS/Cloud IT, outsourcing solutions in healthcare. In addition, the company offers NEXUS/MOBILE for device management, app monitoring, communication, and HIS integration, as well as NEXUS/ECM, NEXUS/E&L, NEXUS/CHILI, NEXUS/PDMS, NEXUS/RIS/PACS, and NEXUS/FOODCARE. NEXUS AG is headquartered in Donaueschingen, Germany.

Details
Name: Nexus AG
NXU
Exchange: XTRA
Founded:
€499,677,852
15,713,140
Website: http://de-de.nexus-ag.de
Address: Nexus AG
Irmastrasse 1,
Donaueschingen,
Baden-Württemberg, 78166,
Germany
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
XTRA NXU Ordinary Shares XETRA Trading Platform DE EUR 24. Jul 2000
DB NXU Ordinary Shares Deutsche Boerse AG DE EUR 24. Jul 2000
LSE 0FGL Ordinary Shares London Stock Exchange GB EUR 24. Jul 2000
SWX NXU Ordinary Shares SIX Swiss Exchange CH CHF 24. Jul 2000
BATS-CHIXE NXUd Ordinary Shares BATS 'Chi-X Europe' GB EUR 24. Jul 2000
Number of employees
Current staff
Staff numbers
1,270
Nexus employees.
Industry
Health Care Technology
Healthcare
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/07/16 21:18
End of day share price update: 2019/07/16 00:00
Last estimates confirmation: 2019/07/11
Last earnings filing: 2019/05/03
Last earnings reported: 2019/03/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.